We are live on
!
Find out more
Kiniksa Pharmaceuticals
KNSA
KNSA
132 hedge funds and large institutions have $659M invested in Kiniksa Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 53 increasing their positions, 45 reducing their positions, and 42 closing their positions.
New
Increased
Maintained
Reduced
Closed
18% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 45
7% more call options, than puts
Call options by funds: $1.34M | Put options by funds: $1.25M
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
9.8% less ownership
Funds ownership: 97.41% → 87.61% (-9.8%)
14% less capital invested
Capital invested by funds: $768M → $659M (-$109M)
14% less funds holding
Funds holding: 154 → 132 (-22)
50% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 42
Holders
132
Holders Change
-22
Holders Change %
-14.29%
% of All Funds
1.91%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
21
Increased
53
Reduced
45
Closed
42
Calls
$1.34M
Puts
$1.25M
Net Calls
+$93K
Net Calls Change
-$1.2M
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$13.4M |
| 2 |
B
Braidwell
Stamford,
Connecticut
|
+$12.5M |
| 3 |
BlackRock
New York
|
+$7.44M |
| 4 |
Millennium Management
New York
|
+$7.17M |
| 5 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$4.18M |
Top Sellers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$58.8M |
| 2 |
Goldman Sachs
New York
|
-$15M |
| 3 |
State Street
Boston,
Massachusetts
|
-$8.82M |
| 4 |
Citigroup
New York
|
-$3.43M |
| 5 |
Pictet Asset Management
Carouge,
Switzerland
|
-$2.94M |
